Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy, Safety and Immunogenicity of LVRNA009 mRNA Vaccine for COVID-19 Prevention
NCT05682638Phase 3Recruiting
- Sponsor
- AIM Vaccine Co., Ltd.
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of LVRNA009 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by AIM Vaccine Co., Ltd. Primary endpoint: Person-year incidence density of first episodes of virologically-confirmed symptomatic cases of COVID-19 of any severity in SARS-CoV-2 naive participants. Started Jan 2023; status: recruiting.
02
Drugs
LVRNA009
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05682638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05682638.